

OMEROS CORP  
Form 8-K  
April 22, 2016

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): April 22, 2016**

**OMEROS CORPORATION**

**(Exact name of Registrant as Specified in Its Charter)**

**Washington**  
**(State or Other Jurisdiction**

**of Incorporation)**

**201 Elliott Avenue West**

**Seattle, WA**

**001-34475**  
**(Commission**

**File Number)**

**91-1663741**  
**(IRS Employer**

**Identification No.)**

**98119**

(Address of Principal Executive  
Offices)

(Zip Code)

Registrant's Telephone Number, Including Area Code: (206) 676-5000

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 7.01 Regulation FD Disclosure.**

On April 22, 2016, Omeros Corporation, or the Company, filed with the U.S. Securities and Exchange Commission, or the SEC, the Company's proxy statement for its 2016 annual meeting of shareholders. This filing was also the remaining condition to effectiveness of the Company's Post-Effective Amendment No. 2 to the Company's Registration Statement on Form S-3 (File No. 333-201581) filed by the company on March 15, 2016. As a result, on April 22, 2016 the Company filed with the SEC necessary updates to previously filed documents.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**OMEROS CORPORATION**

Date: April 22, 2016

By: /s/ Gregory A. Demopoulos  
Gregory A. Demopoulos, M.D.  
President, Chief Executive Officer and  
Chairman of the Board of Directors